title: [Study of gene polymorphism responsible for metabolism of proton pump inhibitors in children with H. pylori infection: is there a correlation with efficacy of eradication treatment?].
abstract: THE AIM of this study was to determine the effects of CYP2C19 polymorphism on H. pylori eradication in pediatric population in the Republic of Bashkortostan.
  
  
  METHODS
  Fifty-nine children were entered into the study (age range: 12 to 17; 22 female). All the patients were infected with H. pylori and received the combination of omeprazole (1 mg/kg/day), furazolidone (10 mg/kg/day) and amoxicilline (25 mg/kg/day) or clarithromycin (7.5 mg/kg/day) for 10 days. The participants were classified into 3 groups according to CYP2C19 genotype; rapid metabolizers (RM) (54.2%), intermediate metabolizers (IM) (35.6%) and poor metabolizers (PM) (10.2%). H. pylori infection status was assessed before and after the treatment.
  
  
  RESULTS
  The eradication rate was 65.6% for RM, 71.4% for IM, and 83.3% for PM.
  
  
  CONCLUSIONS
  The present study confirmed the low eradication rate for RM and for the IM groups. Alternative regimens expected to be with a higher eradication rate should be recommended (rabeprazole-based treatment).
authors.forename: A A
authors.initials: AA
authors.lastname: Nizhevich
authors.forename: B B
authors.initials: BB
authors.lastname: Iunusbaev
authors.forename: M M
authors.initials: MM
authors.lastname: Tuĭgunov
authors.forename: N P
authors.initials: NP
authors.lastname: Tsiglintseva
authors.forename: E K
authors.initials: EK
authors.lastname: Nasretdinova
mesh_terms: D000293:Adolescent; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D002648:Child; D065731:Cytochrome P-450 CYP2C19; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000201:enzymology / Q000382:microbiology; D016480:Helicobacter pylori / Q000187:drug effects* / Q000302:isolation & purification; D006801:Humans; D008658:Inactivation, Metabolic; D008297:Male; D011110:Polymorphism, Genetic; D054328:Proton Pump Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000890:Anti-Infective Agents; D054328:Proton Pump Inhibitors; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19